NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and ...
Marks Strategic U.S. Capital Markets Milestone VANCOUVER, BC AND BREDA, NETHERLANDS / ACCESS Newswire / November 10, 2025 / Organto Foods Inc. (TSX-V:OGO)(OTCQX:OGOFF)(FSE:OGF0) (“Organto” or the ...
ATRN-119 is being evaluated in the open-label Phase 1/2a clinical trial (ABOYA-119) as monotherapy in patients with advanced solid tumors having at least one mutation in a defined panel of DDR-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback